Exhibits G protein-coupled serotonin receptor activity. Involved in several processes, including adenylate cyclase-activating serotonin receptor signaling pathway; generation of neurons; and regulation of neurotransmitter transport. Localizes to several cellular components, including the integral component of synaptic membrane; rough endoplasmic reticulum; and synaptic vesicle. Used to study amnestic disorder; anxiety disorder; childhood absence epilepsy; cognitive disorder; and migraine. Biomarker of irritable bowel syndrome. Human ortholog(s) of this gene implicated in alcohol use disorder. Orthologous to human HTR7 (5-hydroxytryptamine receptor 7); PARTICIPATES IN serotonin signaling pathway via receptors engaging G alphas protein family; calcium/calcium-mediated signaling pathway; INTERACTS WITH 6-propyl-2-thiouracil; ammonium chloride; amphetamine.
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP], Bromocriptine binds to and results in decreased activity of HTR7 protein
HTR7 protein promotes the reaction [[Freund's Adjuvant results in increased activity of TRPV1 protein] which results in increased transport of Calcium]
HTR7 protein promotes the reaction [[Freund's Adjuvant results in increased activity of TRPV1 protein] which results in increased transport of Calcium]
[Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP], Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP] more ...
[Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]
[Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP], Lisuride binds to and results in decreased activity of HTR7 protein
[mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP], mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]
[Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] more ...
[Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP] more ...
[Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP], Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]
[Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP], Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein
2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] more ...
[Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]
[Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
